No­var­tis un­wraps $1.5B gene ther­a­py buy­out — beef­ing up ar­se­nal against reti­nal dis­eases

Christ­mas is com­ing ear­ly for Gy­ro­scope.

In its lat­est gene ther­a­py gam­bit, No­var­tis is pay­ing $800 mil­lion up­front to ac­quire the Syn­cona-backed biotech, with an­oth­er …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER